NFKB1 and B-cell chronic lymphocytic leukemia: It is understood that their resistance to SMAC mimetics, and possibly to chemotherapeutic agents, may be attributed to an elevation in aberrant NF-kB activity in ripoptosome-lacking CLL cells [139].